Please assess the completion status of the following clinical trial:

Trial Title: Safety of and Immune Response to an HIV Vaccine (VRC-HIVDNA009-00-VP) Administered With Interleukin-2/Immunoglobulin (IL-2/Ig) DNA Adjuvant in Uninfected Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria~* HIV negative~* Willing to receive HIV test results~* Good general health~* Acceptable methods of contraception for females of reproductive potential~* Hepatitis B surface antigen negative~* Anti-hepatitis C virus antibody (anti-HCV) negative or negative HCV PCR if anti-HCV is positive~* Normal thyroid stimulating hormone (TSH) level~Exclusion Criteria~* HIV vaccines or placebos in prior HIV vaccine trial~* Immunosuppressive medications within 168 days prior to first study vaccine administration~* Blood products within 120 days prior to first study vaccine administration~* Immunoglobulin within 60 days prior to first study vaccine administration~* Live attenuated vaccines within 30 days prior to first study vaccine administration~* Investigational research agents within 30 days prior to first study vaccine administration~* Subunit or killed vaccines within 14 days prior to first study vaccine administration~* Current tuberculosis prophylaxis or therapy~* Clinical depression with pharmacological treatment within the past 2 years~* Active syphilis~* Serious adverse reaction to vaccines. A person who had an adverse reaction to pertussis vaccine as a child is not excluded.~* Autoimmune disease or immunodeficiency~* Unstable asthma~* Type 1 or Type 2 Diabetes Mellitus~* Thyroid disease requiring treatment~* Serious angioedema within the past 3 years~* Uncontrolled hypertension~* Bleeding disorder~* Malignancy unless it has been surgically removed and, in the opinion of the investigator, is not likely to recur during the study period~* Seizure disorder requiring medication within the past 3 years~* Asplenia~* Mental illness that would interfere with compliance with the protocol~* Other conditions that, in the judgement of the investigator, would interfere with the study~* Pregnant or breast-feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).